Amgen Inc. (NASDAQ:AMGN) is O Brien Greene & Co. Inc’s 5th Largest Position

O Brien Greene & Co. Inc boosted its position in Amgen Inc. (NASDAQ:AMGN) by 11.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 32,405 shares of the medical research company’s stock after acquiring an additional 3,248 shares during the period. Amgen comprises approximately 3.2% of O Brien Greene & Co. Inc’s holdings, making the stock its 5th biggest holding. O Brien Greene & Co. Inc’s holdings in Amgen were worth $10,125,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Aveo Capital Partners LLC grew its stake in Amgen by 19.9% in the 4th quarter. Aveo Capital Partners LLC now owns 2,729 shares of the medical research company’s stock worth $786,000 after acquiring an additional 453 shares during the period. Gryphon Financial Partners LLC boosted its holdings in shares of Amgen by 295.3% in the 4th quarter. Gryphon Financial Partners LLC now owns 3,684 shares of the medical research company’s stock valued at $1,021,000 after purchasing an additional 2,752 shares during the last quarter. Hillsdale Investment Management Inc. boosted its holdings in shares of Amgen by 49.2% in the 4th quarter. Hillsdale Investment Management Inc. now owns 970 shares of the medical research company’s stock valued at $279,000 after purchasing an additional 320 shares during the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in shares of Amgen by 5.7% during the 4th quarter. Gladstone Institutional Advisory LLC now owns 8,300 shares of the medical research company’s stock valued at $2,390,000 after acquiring an additional 449 shares in the last quarter. Finally, Clearbridge Investments LLC lifted its holdings in shares of Amgen by 2.5% during the 4th quarter. Clearbridge Investments LLC now owns 103,117 shares of the medical research company’s stock valued at $29,700,000 after acquiring an additional 2,552 shares in the last quarter. 76.50% of the stock is owned by hedge funds and other institutional investors.

Amgen Price Performance

Shares of NASDAQ:AMGN opened at $332.80 on Wednesday. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The firm has a 50-day simple moving average of $329.00 and a 200 day simple moving average of $304.81. The company has a market cap of $178.53 billion, a PE ratio of 47.54, a P/E/G ratio of 2.93 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion for the quarter, compared to the consensus estimate of $8.35 billion. Amgen had a net margin of 10.12% and a return on equity of 161.72%. Amgen’s quarterly revenue was up 20.1% on a year-over-year basis. During the same period in the prior year, the company earned $5.00 EPS. On average, sell-side analysts anticipate that Amgen Inc. will post 19.49 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Shareholders of record on Friday, August 16th were paid a dividend of $2.25 per share. This represents a $9.00 dividend on an annualized basis and a yield of 2.70%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s payout ratio is 128.57%.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the stock. Jefferies Financial Group restated a “buy” rating and set a $380.00 target price (up previously from $375.00) on shares of Amgen in a report on Wednesday, August 7th. Argus lifted their target price on shares of Amgen from $300.00 to $340.00 and gave the company a “buy” rating in a report on Thursday, June 27th. Wells Fargo & Company lowered shares of Amgen from an “overweight” rating to an “equal weight” rating and lifted their target price for the company from $320.00 to $335.00 in a report on Wednesday, August 7th. Bank of America boosted their price objective on shares of Amgen from $325.00 to $330.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Finally, TD Cowen boosted their price objective on shares of Amgen from $360.00 to $381.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $327.28.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.